ArticleJAC-antimicrobial resistance2024
Carbapenem- and cefiderocol-resistant
Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- A systematic review and meta-analysis of carbapenem-resistant Enterobacteriaceae in West Africa.BMC medical genomics · 2024Pooled it
- Reduced Susceptibility to Cefiderocol Among Clinical MCR-1-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Silent Threat Evolution: Critically Important Carbapenem and Colistin Resistance Genes in the Natural Aquatic Environment.Antibiotics (Basel, Switzerland) · 2026Review
- Importance of wastewater-based and environmental surveillance for monitoring resistance to next-generation antibiotics.Future microbiology · 2025Article
- Cefiderocol-resistant pathogens in German hospital wastewater: a reservoir for multidrug resistance.Scientific reports · 2025Article
- Suppression of gut colonization by multidrug-resistant Escherichia coli clinical isolates through cooperative niche exclusion.Nature communications · 2025Article
- Human-environmental overlap of resistant Enterobacterales: genomic evidence linking coastal waters and community carriage of antimicrobial resistance in a low- and middle-income setting.Frontiers in antibiotics · 2025Article
- A comparativeFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MDR pathogens including ESBL- and/or carbapenemase-producing Objectives: This proof-of-principle study investigated the occurrence of ESBL-PE in surface water in the Ashanti Region in Ghana, sub-Saharan Africa (SSA), and investigated their additional genotypic and phenotypic antimicrobial resistance features as part of the Surveillance Outbreak Response Management and Analysis System (SORMAS). Methods: From 75 water samples overall, from nine small to medium-sized river streams and one pond spatially connected to a channelled water stream in the greater area of Kumasi (capital of the Ashanti Region in Ghana) in 2021, we isolated 121 putative ESBL-PE that were subsequently subjected to in-depth genotypic and phenotypic analysis. Results: Of all 121 isolates, Conclusions: ESBL-PE and CPE occur in surface water sources in and around Kumasi in Ghana. Further surveillance and research are needed to not only improve our understanding of their exact prevalence and the reservoir function of water sources in SSA but should include the investigation of cefiderocol-resistant isolates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.